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Abstract Motivational influence on bradykinesia in Par-
kinson’s disease may be observed in situations of emotional
and physical stress, a phenomenon known as paradoxical
kinesis. However, little is known about motivational mod-
ulation of movement speed beyond these extreme circum-
stances. In particular, it is not known if motivational factors
affect movement speed by improving movement prepara-
tion/initiation or execution (or both) and how this effect
relates to the patients’ medication state. In the present study,
we tested if provision of motivational incentive through
monetary reward would speed-up movement initiation and/
or execution in Parkinson’s disease patients and if this effect
depended on dopaminergic medication. We studied the
effect of monetary incentive on simple reaction time in 11
Parkinson’s disease patients both ‘‘off’’ and ‘‘on’’ dopami-
nergic medication and in 11 healthy participants. The simple
reaction time task was performed across unrewarded and
rewarded blocks. The initiation time and movement time
were quantified separately. Anticipation errors and long
responses were also recorded. The prospect of reward
improved initiation times in Parkinson’s disease patients
both ‘‘off’’ and ‘‘on’’ dopaminergic medication, to a similar
extent as in healthy participants. However, for ‘‘off’’ medi-
cation, this improvement was associated with increased
frequency of anticipation errors, which were eliminated by
dopamine replacement. Dopamine replacement had an
additional, albeit small effect, on reward-related improve-
ment of movement execution. Motivational strategies are
helpful in overcoming bradykinesia in Parkinson’s disease.
Motivational factors may have a greater effect on bradyki-
nesia when patients are ‘‘on’’ medication, as dopamine
appears to be required for overcoming speed-accuracy trade-
off and for improvement of movement execution. Thus,
medication status should be an important consideration in
movement rehabilitation programmes for patients with Par-
kinson’s disease.
Keywords Parkinson’s disease  Bradykinesia 
Motivation  Reward  Reaction time
Introduction
Motivational influence on movement speed is evident in
temporally pressing situations. Common examples include
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working faster when facing a deadline, walking faster
when late for an appointment or achieving personal bests
in sports. Experimental evidence implies that self-deter-
mined ‘‘highest’’ speed of movement is set below the
possible maximum, allowing for an increase of movement
speed in the presence of external challenges or motiva-
tional factors [1–3].
Motivational modulation of movement speed is impor-
tant in understanding variability of bradykinesia in Par-
kinson’s disease (PD) including paradoxical kinesis, which
refers to unique episodes of sudden and brief improve-
ments of mobility in situations of emotional or physical
stress [4, 5]. PD patients also enhance their motor perfor-
mance in response to appropriate auditory, visual or tactile
cues [6, 7] and can benefit from attentional strategies [8],
suggesting that various factors may improve bradykinesia,
possibly through similar mechanisms.
The locus of the effect of motivational influences on
movement speed in PD remains unclear, and it is not
known which specific aspects of movement are affected by
provision of motivational incentive. In particular, it is not
known if manipulation of motivation improves movement
preparation/initiation or execution (or both) and if this
effect depends on the patients’ medication state. One way
to experimentally test motivational influences on move-
ment initiation and execution is through reaction time and
reward studies. We have previously shown in healthy
participants that monetary reward is a relevant incentive
that speeds up reaction times [9]. Here, we tested whether
the prospect of monetary incentive affects initiation time
(IT) and movement time (MT) in PD patients and if this
effect depends on the patients’ medication state. We
evaluated PD patients ‘‘on’’ and ‘‘off’’ dopaminergic
treatment and compared them to healthy participants.
Methods
Participants
We studied 11 patients with idiopathic PD diagnosed
according to UK Brain Bank Criteria [10], without sig-
nificant tremor or dyskinesias (7 men, 4 women, mean age
62, range 50–70) and 11 aged-matched healthy participants
(5 men, 6 women, mean age 61, range 51–70). Patients
were recruited from the PD outpatient clinic at the National
Hospital for Neurology and Neurosurgery in Queen
Square, London. None of the patients had pathological
gambling or other impulse control disorders, as assessed by
the question on dopamine dysregulation syndrome of the
MDS-UPDRS scale (Question 1.6). The clinical and
demographic characteristics of the patients are given in
Table 1. Only patients without previous clinical diagnosis T
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of depression, apathy or cognitive impairment were
included. Healthy participants were recruited from the list
of healthy participants maintained by the Cognitive Motor
Neuroscience Group of the Sobell Department of Motor
Neuroscience and Movement Disorders. They were selec-
ted on the basis of good general health, and none had a
history of neurological or psychiatric illness, head injury or
drug or alcohol misuse. According to the Edinburgh
Handedness Inventory [11] participants were strongly
right-handed (PD patients: mean 85.9, SEM 0.4; Healthy
Participants mean 88.2, SEM 0.32). Written informed
consent was obtained from all participants and the study
was approved by the local ethics committee and conducted
in accordance with the Declaration of Helsinki.
Experimental design
PD patients were studied in two different sessions sepa-
rated by at least 1 week: in the practically defined ‘‘off’’
state after overnight withdrawal of medication and in the
‘‘on’’ state, approximately 1 h after their first morning dose
of the usual medication and once clinical benefit was fully
documented by neurological examination. The order of
‘‘off’’ and ‘‘on’’ sessions was balanced, with five patients
being tested first in the ‘‘off’’ and six in the ‘‘on’’ state.
Healthy participants completed one experimental session
only.
Experimental task: warned and unwarned simple
reaction time
Stimuli were presented on a computer screen and responses
were made on a response box with two buttons: a home key
and a response key (Fig. 1). Two buttons were 2.54 cm in
diameter and placed in a vertical row, spaced 10.16 cm
apart. In each session, participants completed 4 blocks of
100 trials each. Each block consisted of 50 warned simple
reaction times (wSRT) and 50 unwarned simple reaction
times (uSRT) trials randomly mixed. The participants sat in
front of the computer monitor and were instructed to hold
down the home key with the index finger of their right
hand. On pressing the home key a fixation cross appeared
on the screen. On wSRT trials, after a variable delay of
1–4 s, a warning signal (S1) was presented in the form of
an empty square superimposed on the fixation cross. One
thousand six hundred milliseconds later this square was
filled to become solid white, and this constituted the
imperative signal (S2). For wSRT trials, the participants
were instructed to make use of the warning signal and
prepare themselves to respond to presentation of the
imperative signal. On presentation of the imperative signal,
they were required to release the home key as quickly as
possible and press the response key. The screen cleared
500 ms after a response was made. Participants then moved
back to the home key in their own time. The next trial
started when the home key was pressed again. On
unwarned trials (uSRT), there was no S1 or warning signal
and the fixation cross was followed, after a variable delay
of 1–4 s, by a filled square (imperative stimulus), in which
case the participant was required to move to and press the
response key straight away. To discourage anticipatory
responses, they were clearly instructed to wait for presen-
tation of the imperative stimulus. There were five practice
trials to familiarize participants with the stimulus presen-
tation and the response of lifting the index finger from the
‘home’ key and moving to the ‘response’ key.
Provision of monetary incentive for speeding
up reaction times
The blocks were always organised in the same order (two
unrewarded, followed by two rewarded), necessitated by
the need to establish a RT baseline for each participant
before introduction of monetary incentive. First two blocks
were performed without financial incentive, with any
changes in IT and MT from the first to second block pro-
viding a control for changes in ITs and MTs simply as a
result of practice/task repetition effects. Participants were
not told in advance that they would receive any reward in
further blocks. At the end of the second block, participants
were provided with feedback on their reaction time in the
previous block (as an average of IT for uSRT and wSRT
task) and were instructed that, for every 10 ms they spee-
ded their reaction time in the third block, they would
receive a monetary reward of 50 pence. At the end of the
third block, they were again given feedback on their per-
formance and whether they had speeded up relative to the
previous block or not. The amount of money gained was
displayed on the screen. Prior to the fourth block, partici-
pants were instructed that they would receive a monetary
reward of 100 pence for every 5 ms they improved their
reaction times in the following block. The monetary
incentive was real and the participants were provided with
the money gained at the end of the study. Using the same
task without monetary incentive, we have previously
shown that no significant practice effects occur from block
1 to block 4 in healthy participants [9].
Measurement of initiation times, movement times
and errors
The time from presentation of the imperative stimulus to
the release of the ‘home’ key was measured as IT. The time
from release of the ‘home’ key to pressing the ‘response’
key was measured as MT. Both IT and MT were recorded
by the computer to the nearest millisecond. Two types of
1082 J Neurol (2014) 261:1080–1089
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error were recorded: anticipation errors (IT less than or
equal to 100 ms) and long responses (IT greater than
2,000 ms). Trials with error data were excluded and
replaced with a new trial.
Clinical and other measures
Severity of motor symptoms was assessed with the motor
examination sections of the Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) [12]. To screen for depres-
sion, apathy and cognitive impairment, we used the Beck
Depression Inventory (BDI), Marin Apathy Scale (MAS)
and Mini Mental State Examination (MMSE), respectively
[13–15]. The Tridimensional Personality Questionnaire
(TPQ) [16] was used to assess responsiveness to reward,
harm avoidance and novelty seeking dimensions of per-
sonality. PD patients completed the MMSE and TPQ only
once, while they were assessed both ‘‘off’’ and ‘‘on’’
medication for UPDRS, BDI and MAS.
Statistical analysis
Monetary incentive may affect movement initiation and
movement execution differently; therefore, the effect of
monetary incentive on IT and MT was analysed separately.
Since all patients performed the task with their dominant
Fig. 1 Illustration of the simple
reaction time task, showing
events presented on the
computer screen at different
stages of the unwarned and
warned trials
J Neurol (2014) 261:1080–1089 1083
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hand, which in six patients was the more affected and in
five patients the clinically less affected side (even though
all patients had bilateral symptoms at the time of the study,
as evident from the Hoehn and Yahr stage), we first
addressed if the asymmetry of the motor symptoms could
have affected task performance. We conducted a pre-
liminary ANOVA with the PD GROUP (two levels:
patients with the dominant side more affected and patients
with dominant side less affected) as the between-subject
factor, and the within- subjects factors MEDICATION
STATE (‘‘on’’ vs. ‘‘off’’), TASK (wSRT vs. uSRT) and
BLOCK (1–4). We then compared all PD patients ‘‘on’’
and ‘‘off’’ medication in ANOVAs with factors MEDI-
CATION STATE (‘‘on’’ vs. ‘‘off’’), TASK (wSRT vs.
uSRT) and BLOCK (1–4) as within-subject factors. As a
secondary analysis, we assessed how IT and MT compared
between PD patients and healthy participants: data from
PD patients ‘‘on’’ and ‘‘off’’ medication were separately
compared to healthy participants in ANOVAs with the
factor Group (PD ‘‘off’’ vs. healthy participants or PD
‘‘on’’ vs. healthy participants) as a between-subject factor,
and factors TASK and BLOCK as within-subject factors.
Post-hoc Tukey tests with corrections for multiple com-
parisons were used to further analyse significant main
effects or interactions. Group differences in anticipation
errors and long responses were analysed with a non-para-
metric Kruskal–Wallis ANOVA, followed by Wilcoxon
signed rank test or Mann–Whitney U tests. Since clinical
scales are ordinal scales, we compared differences between
PD patients ‘‘off’’ and ‘‘on’’ medication or between patients
and healthy participants, using non-parametric tests. The
significance level was set at p B 0.05.
Results
The scores for the PD patients on UPDRS, MMSE, BDI,
MAS, and TPQ are given in Table 1. For healthy par-
ticipants, the means and standard error of the means
were: BDI 5.81 (1.6); MAS 12.2 (1.53); MMSE 29.5
(0.4); TPQ novelty seeking 14.1 (1.7); TPQ harm
avoidance 13 (2.1); and TPQ reward dependence 15.1
(1.2). As expected, in PD patients total motor UPDRS
was higher in the ‘‘off’’ than the ‘‘on’’ state (z =
-2.973: p = 0.003). There was no difference in BDI and
MAS in PD patients ‘‘off’’ vs. ‘‘on’’ medication. We then
averaged scores for BDI and MAS ‘‘off’’ and ‘‘on’’ and
compared averaged values to those of healthy partici-
pants. PD patients scored worse than healthy participants
on the BDI scale (z = -2.105; p = 0.03), while no
difference was found for MAS, TPQ or MMSE.
The mean values and standard errors of IT and MT
across blocks are shown in Supplementary Table 1.
The effect of asymmetry of motor symptoms on IT
and MT in PD patients
There were no differences between patients with the domi-
nant side less vs. more clinically affected, as revealed by no
significant effect of PD GROUP (IT: F(1,9) = 0.2; p = 0.66
and MT: F(1,9) = 0.31; p = 0.58), or PD GROUP 9
TASK or PD GROUP 9 MEDICATION STATE, PD
GROUP 9 BLOCK or PD GROUP 9 BLOCK 9 MEDI-
CATION STATE interactions. Thus, the clinical asymmetry
of motor symptoms did not affect IT and MT and their
change in response to reward or medication status.
The effect of monetary incentive on IT and MT in PD
patients ‘‘off’’ and ‘‘on’’ medication
Details of the statistical analysis are given in Table 2. For
IT (Fig. 2a, b), the ANOVA revealed a significant main
effect of BLOCK (p \ 0.001), which was due to shorter IT
in the rewarded Blocks 3 and 4 compared to the unre-
warded Block 1 (p = 0.001 and p = 0.001, respectively),
while there were no other differences between blocks
(Block 1 vs. 2, p = 0.2; Block 2 vs. 3, p = 0.3; Block 2
vs.4, p = 0.2 and Block 3 vs. 4, p = 0.9). A 3-way inter-
action: MEDICATION STATE 9 TASK 9 BLOCK
(p = 0.04) was significant, however, post hoc analysis
revealed no differences or trend toward difference in IT
between PD ‘‘off’’ and ‘‘on’’ in any of the four blocks, for
either uSRT or wSRT. These results indicated that PD
patients both ‘‘off’’ and ‘‘on’’ medication initiated their
movement faster in blocks when the reward was provided.
For MT, the effect of monetary incentive was different
between patients ‘‘off’’ and ‘‘on’’ medication (Fig. 2c, d),
as indicated by a significant 3-way interaction MEDICA-
TION STATE 9 TASK 9 BLOCK interaction (F (3,
30) = 3.46; p = 0.03), for which the post hoc analysis
showed to be determined by differences in MT in uSRT
and wSRT depending on medication status. For uSRT, PD
‘‘on’’ were faster than ‘‘off’’ in the unrewarded condition
(Block 2; p = 0.01). Notably, in response to reward, PD
patients had faster MT in ‘‘on’’ than in ‘‘off’’ state for the
wSRT condition (Block 3; p = 0.02).
PD patients, irrespective of medication status, benefited
from a warning signal to initiate and execute the move-
ments faster, as revealed by a significant effect of TASK in
the ANOVAs for both IT and MT (p \ 0.001 and
p \ 0.001, respectively) (Table 2).
The effect of monetary incentive on IT and MT in PD
patients versus healthy participants
For IT, ANOVA (Table 2) confirmed the significant
main effects of TASK and BLOCK noted above, but
1084 J Neurol (2014) 261:1080–1089
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revealed no difference in reward responsiveness between
PD patients (irrespective of treatment status) and healthy
participants, as there were no significant GROUP X
BLOCK or GROUP X TASK X BLOCK interactions.
For PD ‘‘off’’ vs. healthy participants, the factor BLOCK
was significant due to shorter ITs in blocks 3 compared
to both blocks 2 and 1 (p \ 0.001 and p = 0.003,
respectively) and shorter IT in block 4 compared to
block 1 and 2 (p \ 0.001 and p = 0.001, respectively),
while there was no other difference between blocks.
Similarly, for PD ‘‘on’’ vs. healthy participants, the
factor BLOCK was again significant due to shorter ITs
in Blocks 3 compared to Block 2 and 1 (p \ 0.001 and
p = 0.002, respectively) and shorter IT in Block 4
compared to Block 1 and 2 (p \ 0.001 and p = 0.002,
respectively), while there was no other differences
between blocks.
For MT, there was no difference in reward respon-
siveness between patients either ‘‘off’’ or ‘‘on’’ medica-
tion and healthy participants as indicated by no
significant GROUP 9 BLOCK or GROUP 9 TASK 9
BLOCK interactions. PD ‘‘off’’ medication had
significantly slower MTs than healthy participants across
all blocks (main effect of GROUP p = 0.02).
Anticipation errors and long responses
PD patients ‘‘off’’ had a significantly higher number of
anticipation errors (AEs) than ‘‘on’’ medications. (v2 (2,
N = 33) = 25.5; p \ 0.001). This was due to more AE in
rewarded Blocks 3 and 4 (p = 0.01 and p = 0.03,
respectively) in ‘‘off’’ comparing to ‘‘on’’ medications,
while no such difference in AE was present for unrewarded
Blocks 1 and 2 (Supplementary file). Further, analysis
revealed that when ‘‘off’’ medications, PD patients also
made more AEs than healthy participants in the rewarded
Blocks 3 and 4 (p = 0.01 and p = 0.03, respectively), but
not in the unrewarded Blocks 1 and 2. When ‘‘on’’ medi-
cation, no such a difference in AE between PD and the
healthy participants was seen. Importantly, PD patients
‘‘off’’ medications showed a strong positive correlation
between the percentage of improvement of IT in rewarded
blocks and the number of anticipation errors (r = 0.92;
p \ 0.001) (Fig. 3). There was no difference in the number
Table 2 The results of the
separate analyses of variance for
initiation time (IT) and
movement time (MT)
PD Parkinson’s disease
The significant effects are
shown in bold type
IT MT
F (df) p F (df) p
PD ‘‘off’’ vs. PD ‘‘on’’ medication
Medication state 0.63 (1,10) 0.4 0.57 (1,10) 0.5
Task 32.3 (1,10) <0.001 0.32 (1,10) 0.6
Block 7.8 (3,30) <0.001 1.9 (3,30) 0.1
Medication state 9 Task 0.69 (1,10) 0.4 0.14 (1,10) 0.7
Medication state 9 Block 0.31 (3,30) 0.81 0.36 (3,30) 0.8
Block 9 Task 0.91 (3,30) 0.4 0.03 (3,30) 1
Medication state 9 Task 9 Block 3.02 (3,30) 0.04 3.46 (3,30) 0.03
PD ‘‘off’’ medication vs. Healthy Participants
Group 0.98 (1,20) 0.3 6.0 (1,20) 0.02
Task 58 (1,20) <0.001 1,0 (1,20) 0.3
Block 14.7 (3,60) <0.001 1.6 (3,60) 0.2
Group 9 Task 0.48 (1,20) 0.5 (1,20) 0.9
Group 9 Block 2.0 (3,60) 0.1 1,1 (3,60) 0.4
Block 9 Task 1.2 (3,60) 0.3 1.1 (3,60) 0.4
Group 9 Task 9 Block 0.82 (3,60) 0.5 1.14 (3,60) 0.4
PD ‘‘on’’ medication vs. Healthy Participants
Group 1.6 (1,20) 0.2 2.7 (1,20) 0.1
Task 88.7 (1,20) <0.001 0.4 (1,20) 0.5
Block 13.6 (3,60) <0.001 1.2 (3,60) 0.3
Group 9 Task 0.15 (1,20) 0.7 0.23 (1,20) 0.6
Group 9 Block 0.75 (3,60) 0.5 0.15 (3,60) 0.9
Block 9 Task 3.73 (3,60) 0.02 1.6 (3,60) 0.2
Group 9 Task 9 Block 0.09 (3,60) 1 1.19 (3,60) 0.3
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of long responses between PD patients ‘‘off’’ and ‘‘on’’
medication or between PD patients and controls (median 0,
range 0-3 across all four blocks).
None of the Spearman correlations between MAS, BDI,
MMSE or TPQ and IT or MT were notable or significant
for PD patients or healthy participants.
Discussion
The main findings of the present study are: (1) The pros-
pect of reward improved movement initiation in PD
patients irrespective of their medication status and to a
similar extent as in healthy participants. (2) For patients
tested ‘‘off’’ medication, reward-related improvement of
movement speed was associated with an increased fre-
quency of anticipation errors. (3) Dopamine replacement
eliminated the anticipation errors and also influenced the
reward-related improvement of movement execution.
Our finding that even ‘‘off’’ medication patients
improved their ITs with the prospect of monetary incentive
(Fig. 2a,b) may perhaps be surprising, but is consistent
with previous studies, which demonstrated a preserved
ability of PD patients to translate the expectation of reward
into generation of faster movements or greater physical
force, even when unmedicated. For example, non-apathetic
bradykinetic PD patients ‘‘off’’ medication, in the presence
of monetary incentive, were able to increase hand grip
force [17] or to complete a spatial search task faster [18].
Nevertheless, our results are different from those of Shiner
et al. [19], who reported that PD patients ‘‘off’’ dopami-
nergic treatment failed to modulate movement speed in the
face of monetary reward. However, since these authors
considered only changes in MT, improvements in IT that
we describe here, could have been missed.
There are several possible explanations for our finding
that PD patients ‘‘off’’ dopaminergic treatment behave no
differently than ‘‘on’’ treatment when the effect of mone-
tary incentive on IT is concerned. First, it has been sug-
gested that the neurodegenerative process in early PD
selectively spares dopaminergic limbic circuits that medi-
ate motivational influences on behaviour [20–22], while
preferentially affecting the nigrostriatal dopaminergic
projections responsible for bradykinesia. Indeed, circuits
believed to mediate motivational influences on behaviour
that originate from the anterior cingulate and orbitofrontal
cortices and then synapse on the ventral striatum and
ventral pallidum, remain relatively unaffected until the
advanced stages of PD [23]. Second, an alternative expla-
nation is engagement of compensatory circuits during
reward-related tasks. PD patients ‘‘off’’ treatment could
have made faster movements in the presence of monetary
incentive by using dopamine-independent compensatory
pathways. It has been found that compensatory cerebellar
activation underpins motivational modulation of motor
behaviour in non-medicated PD patients [1, 3, 18, 24, 25].
A compensatory role of cerebellar circuitry has also been
hypothesized by Keefe et al. [26] and Glickstein and Stein
[27] in paradoxical kinesis and demonstrated in imaging
studies of motor urgency in PD [20, 24]. Third, our results
could also be considered within the theoretical framework
that proposes dual, goal-directed and habitual systems of
movement control [28]. Studies in animals and humans
have identified spatially segregated functional territories in
the basal ganglia for the control of goal-directed and
habitual actions [29, 30]. In PD, loss of dopamine is
a b
c d
Fig. 2 Initiation time (IT) and
Movement time (MT) data for
PD patients ‘‘off’’and
‘‘on’’medication and for healthy
participants in the unwarned
simple reaction time (uSRT)
and warned simple reaction time
(wSRT) task. Error bars are
standard error of the mean. Data
presented are the raw data.
Blocks 1 and Block 2 are
unrewarded blocks; Blocks 3
and Block 4 are rewarded
blocks
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predominantly in the posterior putamen [31], a region of
the basal ganglia, which is preferentially activated in situ-
ations when habitual control of movement is implicated.
The prospect of reward could have switched motor control
from habitual to a goal-directed mode, mediated by the
comparatively preserved processing in the rostromedial
striatum, thus, resulting in faster movements.
It has been suggested that the motor system has its own
motivation circuit, which operates implicitly (i.e., outside
awareness) to direct behaviour [19, 32]. The proposal is that
movement speed is determined implicitly by a value
assigned to the goal of the movement. How fast one moves
will depend on the optimal balance between the ‘‘cost’’ of
movement, i.e., time and effort necessary to complete the
action, and the reward obtainable in the particular behav-
ioural setting [5, 32]. According to this model, bradykinesia
in PD is a result of a shift in the cost/benefit ratio towards
slower movements,caused by dopaminergic deficit. PD
patients might find it more of an effort to move fast and
would implicitly prefer slower movements [5], despite the
repertoire of normal movements being preserved, as evi-
denced by improvements in movement speed in response to
different types of cueing, reward or in stressful situations [20,
32, 33]. Accordingly, a provision of explicit monetary
incentive in our experiment could override the implicit
energetic cost bias hypothesised by Mazzoni et al. [32] and
thus change the cost/benefit ratio toward faster movements.
A novel finding of the present study is that certain
aspects of the effect of motivation on movement speed
(induced by the prospect of a monetary incentive) were
differently modulated in PD patients depending on their
medication status. In our patients, provision of monetary
incentive differentially affected movement execution
depending on dopaminergic status, as only patients ‘‘on’’
medication improved MT in response to a prospect of
reward (Fig. 2d). Dopamine neurotransmission is known to
exert a powerful influence over movement vigour, that is
the likelihood of moving at a certain speed or strength; and
motivational impact on movement depends on tonic
dopamine release in the nigrostriatal circuits [33–35]. We,
thus, speculate that the medication effect on MT may have
been mediated through dopaminergic modulation of
movement vigour. Indeed, a recent study using a temporal
decision making task also showed that a tendency to adapt
response times to achieve maximal reward depends on
patients’ medication status [36]. In addition, in PD patients
‘‘off’’ treatment improvement of ITs in response to pros-
pect of monetary reward was associated with increased
frequency of anticipation errors, which was then eliminated
in the ‘‘on’’ state (Fig. 3). Therefore, our results suggest
that dopamine was required for avoiding speed-accuracy
trade-offs during movement execution, by preventing pre-
mature responses.
Finally, in the overall interpretation of our results we
should consider also the effect of attention. It is known that
focusing attention on movement effect (i.e., goal of the
movement) rather than focusing on movement itself (i.e.,
execution of movement) enhance motor performance and
Fig. 3 PD patients ‘‘off’’medication showed a significant positive
correlation between improvement of IT in response to prospect of
monetary reward and the number of anticipation errors, suggestive of
‘‘speed-accuracy trade-off’’. This association was not present in PD
patients ‘‘on’’ medication or in healthy participants. Percentage of IT
improvement is plotted on the x-axis and larger values correspond to
greater improvement in IT in response to prospect of reward.
Difference in anticipation errors between rewarded and unrewarded
blocks is plotted on the y-axis and a larger value indicates more
anticipation errors in rewarded trials
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improves both movement speed and accuracy of movement
[37, 38]. Levodopa or dopamine agonists improve attention
span and vigilance [36] and attentional strategies help to
improve motor speed and accuracy of movement in PD
patients ‘‘on’’ medication [32]. Thus, improved focusing of
attention with prospect of reward could have acted syner-
gistically with dopamine replacement and the presence of
temporal cueing in the wSRT task [36], resulting not only
in improvement of MT, but also (by keeping premature
responses in check and preventing anticipatory errors) in
overall more accurate performance in the ‘‘on’’ state.
Similar to our previous investigation in young healthy
participants [9], in the present study the reward magni-
tude had no significant effect on speeding up RTs, as
there was no further improvement either in movement
initiation or execution times in response to a higher level
of reward. This is likely due to a ‘‘ceiling’’ effect, as
participants could have already exceeded their self-
determined maximal movement speed with the first level
of the reward.
A limitation of our study was that the blocks were
always organised in the same order (two unrewarded, fol-
lowed by two rewarded), dictated by the need to establish a
RT baseline for each participant before introduction of
monetary incentive. We cannot exclude that the improve-
ment in rewarded blocks was affected by practice. How-
ever, this seems unlikely, because previous studies showed
no evidence of such practice effects across repeated blocks
in PD patients or in healthy participants [9, 19, 39]. Fur-
thermore, we observed no significant speeding of RTs from
the unrewarded Block 1 to Block 2. Another potential
limitation is that PD patients completed the task twice
(‘‘off’’ and ‘‘on’’ medication) and therefore were aware of
the experimental design when they performed the task for
the second time. However, as the order of ‘‘off’’ and ‘‘on’’
sessions was counterbalanced across patients, we believe
this potential confounding effect was minimized and did
not influence the results. In future studies, a subjective
rating of the value of the monetary reward to participants
would help establish its motivational and incentivizing
impact in each case.
Conclusions
Slowness of movement in PD may be improved in
exceptional situations that trigger paradoxical kinesis [4,
5] or when external stimuli for the guidance of move-
ment are provided 8, 40]. Here, we show that motiva-
tional processes, over and above emotional influences or
sensory cueing, may challenge and overcome bradyki-
nesia in PD. This motivational modulation of movement
speed seems to be more efficient during the medicated
(‘‘on’’) state, which may have implications for choosing
the most appropriate conditions for rehabilitation of PD
patients.
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